These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 18482285)
1. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. Chou R; Carson S; Chan BK J Viral Hepat; 2008 Aug; 15(8):551-70. PubMed ID: 18482285 [TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877 [TBL] [Abstract][Full Text] [Related]
3. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis. Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Druyts E; Thorlund K; Wu P; Kanters S; Yaya S; Cooper CL; Mills EJ Clin Infect Dis; 2013 Apr; 56(7):961-7. PubMed ID: 23243171 [TBL] [Abstract][Full Text] [Related]
6. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553 [TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Chou R; Hartung D; Rahman B; Wasson N; Cottrell EB; Fu R Ann Intern Med; 2013 Jan; 158(2):114-23. PubMed ID: 23437439 [TBL] [Abstract][Full Text] [Related]
9. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815 [TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C; JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915 [TBL] [Abstract][Full Text] [Related]
11. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT; N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351 [TBL] [Abstract][Full Text] [Related]
12. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Koretz RL; Pleguezuelo M; Arvaniti V; Barrera Baena P; Ciria R; Gurusamy KS; Davidson BR; Burroughs AK Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD003617. PubMed ID: 23440791 [TBL] [Abstract][Full Text] [Related]
13. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. McHutchison J; Sulkowski M J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672 [TBL] [Abstract][Full Text] [Related]
14. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960 [TBL] [Abstract][Full Text] [Related]
15. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. El Makhzangy H; Esmat G; Said M; Elraziky M; Shouman S; Refai R; Rekacewicz C; Gad RR; Vignier N; Abdel-Hamid M; Zalata K; Bedossa P; Pol S; Fontanet A; Mohamed MK J Med Virol; 2009 Sep; 81(9):1576-83. PubMed ID: 19626613 [TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016 [TBL] [Abstract][Full Text] [Related]
17. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332 [TBL] [Abstract][Full Text] [Related]
18. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174 [TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed. Prescrire Int; 2003 Dec; 12(68):206-10. PubMed ID: 14986684 [TBL] [Abstract][Full Text] [Related]